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`    Experimental design
1.   Sample size
Describe how sample size was determined. The antibodies in this study were previously isolated. The only real sample size calculations 
pertain to the animal studies. These mouse and guinea pig studies are constrained in that 
they require BSL-4 challenge facilities, which are a limited resource. We determined the 
group sizes that would show statistically and biologically meaningful differences based on 
many years of studies at UTMB on antivirals, antibodies and vaccines for ebolaviruses.
2.   Data exclusions
Describe any data exclusions. No data were excluded.
3.   Replication
Describe the measures taken to verify the reproducibility 
of the experimental findings.
Findings presented were based on independent experiments or replicates, as stated in the 
figure legends. The number of samples was the minimum number required to obtain 
scientifically valid results. For in vivo experiments, we included justification for group size 
through a power analysis when possible. All attempts at replication in the stated conditions 
were successful.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
In Figure 2, mice and guinea pigs were allocated randomly into each treatment group.
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
Five animals per experimental group were used, based on 100% mortality following infection 
with filoviruses, which allowed statistical assessment at the 95% confidence level (1-tailed 
Fisher exact test). The animals were randomly assigned for the experimental groups. UTMB 
Animal Resource Center veterinary staff was blinded for the antibodies' administration to 
experimental groups.     
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.






6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present 
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
`   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
Prism version 5 (GraphPad), Appion platform (Lander G. C., 2009), DoG Picker ( Voss, N. R., 
1009).
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
`   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a third party.
Antibodies described in this paper are available under MTA from Vanderbilt University 
Medical Center.
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
Human antibodies used were generated as part of our study using previously described 
methods (Flyak AI, Cell 2016; 164: 392-405. PMC ID 4733404.) 
The following secondary antibodies were used were validated in the previous study: 
goat anti-human IgG alkaline phosphatase conjugate (Meridian Life Science #W99008A) and  
anti-human Alexa Fluor 488-conjugate (Jackson ImmunoResearch Laboratories, Westgrove, 
PA).
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. Vero-E6 cell line was obtained from the American Type Culture Collection. FreeStyle 293F cell 
line was purchased from Thermo Fisher Scientific.
b.  Describe the method of cell line authentication used. STR testing.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
All cell lines were tested on a monthly basis for Mycoplasma and found to be negative in all 
cases.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.






`    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide all relevant details on animals and/or 
animal-derived materials used in the study.
The animal protocols for testing of mAbs in mice and guinea pigs were approved by the 
Institutional Animal Care and Use Committee of the UTMB and performed in the ABSL-4 
facility of the Galveston National Laboratory. The 7-8-week-old female BALB/c mice (Charles 
River Laboratories) at five animals per group were injected with 1,000 PFU of the mouse-
adapted EBOV, strain Mayinga, by the intraperitoneal route. 24 hours later, animals were 
injected with individual mAbs at 100 μg per animal by the intraperitoneal route. Animals 
treated withthe antibody specific to dengue virus 2D22 served as controls. Mice were 
monitored twice daily from day 0 to day 14 post challenge, followed by once daily monitoring 
from day 15 to the end of the study at day 28. The disease was scored using the following 
parameters: dyspnea (possible scores 0-5), recumbency (0-5), unresponsiveness (0-5), and 
bleeding/hemorrhage (0-5). All mice were euthanized at day 28 post EBOV challenge. 
To test the protective efficacy of mAbs in guinea pigs (strain Hartley), five- to six-week-old 
female guinea pigs at five animals per group were injected with 1,000 PFU of guinea pig-
adapted EBOV, strain Mayinga, by the intraperitoneal route. 24 hours later, animals were 
injected with individual mAbs at 5 mg per animal by the intraperitoneal route. Animals were 
monitored and weighed daily for 28 days. After animals became symptomatic, they were 
examined no less than twice per day. The disease was scored using the same parameters as 
used for mice. All guinea pigs were euthanized at day 28 post EBOV challenge. 
Groups of 6-month-old male and female animals (Mustela putorius furo, Marshall 
BioResources) were challenged intramuscularly with 1,000 pfu of BDBV as described 
previously. Animals were treated with 20 mg of BDBV223 or control 2D22 antibody on day 3, 
and the same dose of the antibody on day 6 after challenge. The disease scores were 
assessed as follows: healthy, 1; developing clinical disease, 2; advanced disease, 3; moribund, 
4. Ferrets were monitored for 28 days after infection and then euthanized.
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
None.
